<DOC>
	<DOC>NCT00452985</DOC>
	<brief_summary>Primary objective: To assess response rate. To record the clinical improvement in relation to stage and histopathological grading. Secondary objective: To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.</brief_summary>
	<brief_title>Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Performance status Karnofsky index ≥ 60%. Early stage as well as advanced/metastatic ovarian cancer proven by abdominal ultrasonography, chest xray, Computerized axial tomography scan. Histologically: epithelial/germ cell Haematology: absolute neutrophil count: ≥2X10^9/L; Platelet: ≥150X10^9/L; Haemoglobin: ≥ 10g/dL Liver function: total bilirubin: ≤1X UNL (upper normal limit); Aspartate transaminase &amp; Alanine aminotransferase: ≤2.5 x UNL; Alkaline phosphatase: ≤2.5 UNL Renal function: Creatinine: ≤130 µmol/L; If creatinine &gt; 130 µmol/L, the 24 hour creatinine clearance should be &gt; 60 ml/min. Symptomatic peripheral neuropathy &gt; grade 1 by National Cancer Institute Common Toxicity Criteria scale Uncontrolled diabetes mellitus and uncontrolled hypertension Pregnant, or lactating patients(patients of childbearing potential must be using adequate contraception). Active infection or other serious underlying medical condition not compatible with program entry eg. congestive heart failure, previous myocardial infarction within 6 months prior to treatment. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>